WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 1827

Legislative bill overview

SB 1827 relates to investigational stem cell treatment regulations in Texas. The bill was recently filed and referred to the Health & Human Services Committee. As of the available information, specific provisions have not yet been detailed in public documents, though the title suggests it addresses how Texas regulates access to experimental stem cell therapies.

Why is this important

Stem cell treatments represent a significant frontier in medical research, with potential applications for degenerative diseases, injuries, and chronic conditions. Texas regulations in this area could affect patient access to experimental therapies, medical provider liability, and the state's competitive position in regenerative medicine research and commercialization.

Potential points of contention

  • Patient protection vs. access balance: Determining how much regulatory oversight is appropriate versus allowing patients access to potentially beneficial experimental treatments
  • Safety and efficacy standards: Disagreement over what evidence should be required before treatments can be offered, particularly for unproven therapies
  • Provider liability and accountability: Questions about legal responsibility if investigational treatments cause harm and whether providers should have liability protections for offering experimental care

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.